Non-alcoholic Steatohepatitis and Cancer

Clinics in Liver Disease

Volumn 11, Issue 1, 2007, Pages 191-207

  Bugianesi, E ^a  

^a MOLINETTE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL LIVER DISEASE; BODY MASS; CANCER RISK; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; FOLLOW UP; HEMOCHROMATOSIS; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HYPERLIPIDEMIA; INSULIN RESISTANCE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; OBESITY; OXIDATIVE STRESS; REVIEW; RISK FACTOR; VIRUS HEPATITIS;

CARCINOMA, HEPATOCELLULAR; FATTY LIVER; HEPATITIS; HUMANS; LIVER NEOPLASMS; METABOLIC SYNDROME X; OBESITY;

EID: 34249699540     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2007.02.006     Document Type: Review

References (70)

1. Ferlay J., Bray F., and Pisani D.M. GLOBOCAN 2000: cancer incidence, mortality and prevalence worldwide. Version 1.0 (2001), IARC Press, Lyon (France)
2. Bosch F.X., Ribes J., Diaz M., et al. Primary liver cancer: worldwide incidence and trends. Gastroenterology 127 (2004) S5-S16
3. El-Serag H.B., and Mason A.C. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340 (1999) 745-750
4. El-Serag H.B., and Mason A.C. Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med 160 (2000) 3227-3230
5. Di Bisceglie A.M., Lyra A.C., Schwartz M., et al. Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. Am J Gastroenterol 98 (2003) 2060-2063
6. Dyer Z., Peltekian K., and Veldhuyzen Van Zanten S. Review article: the changing epidemiology of hepatocellular carcinoma in Canada. Aliment Pharmacol Ther 22 (2005) 17-22
7. Liang T.J., Jeffers L.J., Reddy K.R., et al. Viral pathogenesis of hepatocellular carcinoma in the United States. Hepatology 18 (1993) 1326-1333
8. McCullough A.J. The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin Liver Dis 8 (2004) 521-533
9. Bugianesi E., Zannoni C., Vanni E., et al. Non-alcoholic fatty liver and insulin resistance: a cause-effect relationship?. Dig Liver Dis 36 (2004) 165-173
10. Bugianesi E., Leone N., Vanni E., et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 123 (2002) 134-140
11. Marrero J.A., Fontana R.J., Su G.L., et al. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 36 (2002) 1349-1354
12. Ratziu V.D., Bonyhay L., Di Martino V., et al. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology 35 (2002) 1485-1493
13. Regimbeau J.M., Colombat M., Mogol P., et al. Obesità and diabetes as a risk factor for hepatocellular carcinoma. Liver Transpl 10 (2004) S69-S73
14. Powell E.E., Cooksley W.G., Hanson R., et al. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 11 (1990) 74-80
15. Poonawala A., Nair S.P., and Thuluvath P.J. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. Hepatology 32 (2000) 689-692
16. Italian Multicentre Cooperative project on nutrition in liver cirrhosis. Nutritional status in cirrhosis. J Hepatol 21 (1994) 317-325
17. Mofrad P., Contos M.J., Haque M., et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 37 (2003) 1286-1292
18. Cotrim H.P., Parana R., Braga E., et al. Nonalcoholic steatohepatitis and hepatocellular carcinoma: natural history?. Am J Gastroenterol 95 (2000) 3018-3019
19. Zen Y., Katayanagi K., Tsuneyama K., et al. Hepatocellular carcinoma arising in non-alcoholic steatohepatitis. Pathol Int 51 (2001) 127-131
20. Orikasa H., Ohyama R., Tsuda N., et al. Lipid-rich clear cell hepatocellular carcinoma arising in non-alcoholic steatohepatitis in a patient with diabetes mellitus. J Submicrosc Cytol Pathol 35 (2001) 195-200
21. Shimada M., Hashimoto E., Taniai M., et al. Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. J Hepatol 37 (2002) 154-160
22. Mori S., Yamasaki T., Sakaida I., et al. Hepatocellular carcinoma with nonalcoholic steatohepatitis. J Gastroenterol 39 (2004) 391-396
23. Bullock R.E., Zaitoun A.M., Aithal G.P., et al. Association of non-alcoholic steatohepatitis without significant fibrosis with hepatocellular carcinoma. J Hepatol 41 (2004) 685-690
24. Yoshioka Y., Hashimoto E., Yatsuji S., et al. Nonalcoholic steatohepatitis: cirrhosis, hepatocellular carcinoma and burn-out NASH. J Gastroenterol 39 (2004) 1215-1218
25. Sato K., Ueda Y., Ueno K., et al. Hepatocellular carcinoma and nonalcoholic steatohepatitis developing during long-term administration of valproic acid. Virchows Arch 447 (2005) 996-999
26. Ikeda H., Suzuki M., Takahashi H., et al. Hepatocellular carcinoma with silent and cirrhotic non-alcoholic steatohepatitis, accompanying ectopic liver tissue attached to gallbladder. Pathol Int 56 (2006) 40-45
27. Fassio E., Alvarez E., Dominguez N., et al. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology 40 (2004) 820-826
28. Harrison S.A., Torgerson S., and Hayashi P.H. The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. Am J Gastroenterol 98 (2003) 2042-2047
29. Hui J.M., Kench J.G., Chitturi S., et al. Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology 38 (2003) 420-427
30. Adams L.A., Lymp J.F., St Sauver J., et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 129 (2005) 113-121
31. Caldwell S.H., and Crespo D.M. The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease. J Hepatol 40 (2004) 578-584
32. Calle E.E., Rodriguez C., Walker-Thurmond K., et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S adults. N Engl J Med 348 (2003) 1625-1638
33. Calle N.E.J.M., Samanic C., Gridley G., et al. Obesity and cancer risk among white and black United States veterans. Cancer Causes Control 15 (2004) 35-43
34. Moller H., Mellemgaard A., Lindvig K., et al. Obesity and cancer risk: a Danish record-linkage study. Eur J Cancer 30A (1994) 344-350
35. Wolk A., Gridley G., Svensson M., et al. A prospective study of obesity and cancer risk (Sweden). Cancer Causes Control 12 (2001) 13-21
36. Oh S.W., Yoon Y.S., and Shin S.A. Effects of excess weight on cancer incidences depending on cancer sites and histologic findings among men: Korea National Health Insurance Corporation Study. J Clin Oncol 23 (2005) 4742-4754
37. Pan S.Y., Johnson K.C., Ugnat A.M., et al., Canadian Cancer Registries Epidemiology Research Group. Association of obesity and cancer risk in Canada. Am J Epidemiol 159 (2004) 259-268
38. Ahn Y.O. Strategy for vaccination against hepatitis B in areas with high endemicity: focus on Korea. Gut 38 (1996) S63-S66
39. Nair S., Mason A., Eason J., et al. Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis?. Hepatology 36 (2003) 150-155
40. Adami H.O., Chow W.H., Nyren O., et al. Excess risk of primary liver cancer in patients with diabetes mellitus. J Natl Cancer Inst 89 (1996) 317-318
41. Yu M.C., Tong M.J., Govindarajan S., et al. Nonviral risk factors for hepatocellular carcinoma in a low-risk population, the non-Asians of Los Angeles County, California. J Natl Cancer Inst 83 (1991) 1820-1826
42. Wideroff L., Gridley G., Mellemkjaer L., et al. Cancer incidence in a population based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst 89 (1997) 1360-1365
43. Lagiou P., Kuper H., Stuver S.O., et al. Role of diabetes mellitus in the etiology of hepatocellular carcinoma. J Natl Cancer Inst 92 (2000) 1096-1099
44. Hassan M.M., Hwang L.Y., Hatten C.J., et al. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology 36 (2002) 1206-1213
45. El-Serag H.B., Richardson P.A., and Everhart J.E. The role of diabetes in hepatocellular carcinoma: a case-control study among United States Veterans. Am J Gastroenterol 96 (2001) 2462-2467
46. Davila J.A., Morgan R.O., Shaib Y., et al. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut 54 (2005) 533-539
47. El-Serag H.B., Tran T., and Everhart J.E. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 126 (2004) 460-468
48. Caldwell S.H., Crespo D.M., Kang H.S., et al. Obesity and hepatocellular carcinoma. Gastroenterology 127 (2004) S97-S103
49. Calle E.E., and Kaaks S. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 4 (2004) 579-591
50. World Health Organization. Obesity epidemic puts millions at risk for related diseases [press release WHO/46]. Available at: http://www.who.int/archives/inf-pr-1997/en/pr97-46.html.
51. IARC. IARC handbooks of cancer prevention. Weight control and physical activity (2002), International Agency for Research on Cancer, Lyon (France)
52. Mokdad A.H., Ford E.S., Bowman B.A., et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 289 (2003) 76-79
53. Canman C.E., and Kastan M.B. Induction of apoptosis by tumor suppressor genes and oncogenes. Semin Cancer Biol 6 (1995) 17-25
54. Leclerq I.A., and Farrell G.C. Leptin is required for the development of hepatic fibrosis. Hepatology 32 (2000) 302A
55. Yang S.Q., Lin H.Z., Hwang J., et al. Hepatic hyperplasia in noncirrhotic fatty livers is obesity-related hepatic steatosis a premalignant condition?. Cancer Res 61 (2001) 5016-5023
56. Yang S.Q., Zhu H., Li Y., et al. Mitochondrial adaptations to obesity-related oxidant stress. Arch Biochem Biophys 378 (2000) 259-268
57. Browning J.D., and Horton J.D. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 114 (2004) 147-152
58. Loffreda S., Yang S.Q., Lin H.Z., et al. Leptin regulates proinflammatory immune responses. FASEB J 12 (1998) 57-65
59. Yu S., Rao S., and Reddy J.K. Peroxisome proliferator-activated receptors, fatty acid oxidation, steatohepatitis and hepatocarcinogenesis. Curr Mol Med 3 (2003) 561-572
60. Hu W., Feng Z., Eveleigh J., et al. The major lipid peroxidation product, trans-4-hydroxy-2-nonenal, preferentially forms DNA adducts at codon 249 of human p53 gene, a unique mutation hotspot in hepatocellular carcinoma. Carcinogenesis 23 (2000) 1781-1789
61. Xu Z., Chen L., Leung L., et al. Liver-specific inactivation of the Nrf1 gene in adult mouse leads to nonalcoholic steatohepatitis and hepatic neoplasia. Proc Natl Acad Sci U S A 102 (2005) 4120-4125
62. Fang C.H., Gong J.Q., and Zhang W. Function of oval cells in hepatocellular carcinoma in rats. World J Gastroenterol 10 (2004) 2482-2487
63. Li M.Y., Deng H., Zhao J.M., et al. Peroxisome proliferator-activated receptor gamma ligands inhibit cell growth and induce apoptosis in human liver cancer BEL-7402 cells. World J Gastroenterol 9 (2003) 1683-1688
64. Brakenhielm E., Veitonmaki N., Cao R., et al. Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci U S A 101 (2004) 2476-2481
65. Knight B., Yeap B.B., Yeoh G.C., et al. Inhibition of adult liver progenitor (oval) cell growth and viability by an agonist of the peroxisome proliferator activated receptor (PPAR) family member gamma, but not alpha or delta. Carcinogenesis 26 (2005) 1782-1792
66. Ish-Shalom D., Christoffersen C.T., Vorwerk P., et al. Mitogenic properties of insulin and insulin analogues mediated by the insulin receptor. Diabetologia 40 (1997) S25-S31
67. Chou C.K., Ho L.T., Ting L.P., et al. Selective suppression of insulin-induced proliferation of cultured human hepatoma cells by somatostatin. J Clin Invest 79 (1987) 175-178
68. Alexia C., Fallot G., Lasfer M., et al. An evaluation of the role of insulin-like growth factors (IGF) and of type-I IGF receptor signalling in hepatocarcinogenesis and in the resistance of hepatocarcinoma cells against drug-induced apoptosis. Biochem Pharmacol 68 (2004) 1003-1015
69. Tanaka K., Sakai H., Ashizume M., et al. Serum testosterone:estradiol ratio and the development of hepatocellular carcinoma among male cirrhotic patients. Cancer Res 60 (2000) 5106-5110
70. Rajala M.W., and Scherer P.E. Minireview: the adipocyte-at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology 144 (2003) 3765-3773